---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060518"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:12:06.569991+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis AD Phase II/III shows significant cognition improvement; PD topline due June 2024; Q1 cash $3.1M

## Summary
- Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).
- Phase II/III AD: ADAS-Cog 11 improvement 3.3 pts vs 0.3 for placebo at 3 months; plan 18-month Phase III trial.
- PD Phase III unblinded; topline results expected June 2024; 523 patients randomized, 471 completed.
- Net loss per share $0.10 basic, $0.72 diluted; includes $6.7M non-cash gain from warrant revaluation.
- Filed patent application for buntanetap in neuropsychiatric disorders including autism, ADHD, depression.

## SEC filing metadata
- accession: 0001104659-24-060518
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/0001104659-24-060518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/tm2414281d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060518
- JSON: https://secwatch.observer/filing/0001104659-24-060518.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060518.txt

## Key facts
- Earnings Releases
  Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/0001104659-24-060518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.